What is the cost-effectiveness of veliparib in combination with carboplatin and paclitaxel, compared to carboplatin with paclitaxel only, for patients with BRCA-positive, triple-negative, or HER2-negative, advanced breast cancer, who received up to two chemotherapy regimens for advanced disease, in the UK?

Scheffer Apecechea, N.J.

2021-07-16

Additional Metadata
Keywords	cost-effectiveness;breast cancer;veliparib
Thesis Advisor	Penton, H.
Persistent URL	hdl.handle.net/2105/62521
Series	Master Health Economics, Policy and Law
Organisation	Erasmus School of Health Policy & Management
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Scheffer Apecechea, N.J. (2021, July 16). What is the cost-effectiveness of veliparib in combination with carboplatin and paclitaxel, compared to carboplatin with paclitaxel only, for patients with BRCA-positive, triple-negative, or HER2-negative, advanced breast cancer, who received up to two chemotherapy regimens for advanced disease, in the UK?. Master Health Economics, Policy and Law. Retrieved from http://hdl.handle.net/2105/62521

Publication